We Work for Health Virginia

11/03/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Merck's new $3 billion facility in Virginia marks a significant investment in U.S. drug manufacturing, driven by supportive government policies and incentives for biotech companies. f Virginians want more groundbreaking ceremonies like this, we need those policymakers to keep incentivizing research,...

11/03/2025

: "Governor Glenn Youngkin announced a landmark partnership with AstraZeneca, Eli Lilly and Company, and Merck that commits up to $120 million of private industry investment toward developing the Virginia Center for Advanced Pharmaceutical Manufacturing."

Governor Glenn Youngkin, 74th Governor of Virginia

10/28/2025

China is rapidly expanding clinical trials and IPOs, while the U.S. is getting additional investments in R&D and facility infrastructure. Now policymakers must ensure America stays ahead. Senate HELP Committee is holding a hearing, “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients” on 10/29/

WASHINGTON – On Wednesday, October 29, the Senate Health, Education, Labor, and Pensions (HELP) Committee will hold a hearing on how we can better...

10/27/2025

"Pharmaceutical company Merck will make a $3 billion investment into building a manufacturing facility that’ll bring jobs to Rockingham County, according to Governor Glenn Youngkin."

The pharmaceutical manufacturing facility will be 400,000 square feet.

10/21/2025

"Pharmaceutical giant Merck & Co. is breaking ground on a $3 billion expansion of its longtime Elkton manufacturing campus, a project state and federal officials say will transform the Shenandoah Valley into a hub for life sciences innovation while adding as many as 500 permanent jobs."

Pharmaceutical giant Merck & Co. is breaking ground on a $3 billion expansion of its longtime Elkton manufacturing campus, a project state and federal officials say will transform the Shenandoah Valley into a hub for life sciences innovation while adding as many as 500 permanent jobs.The 400,000-squ...

10/14/2025

"Established to help our most vulnerable patients access essential medications, this well-intentioned program has been hijacked by large hospital and pharmacy systems thereby raising health care costs for all Virginians by inflating the cost of these discounted drugs."

Read more about the 340B program:

Established to help our most vulnerable patients access essential medications, the well-intentioned federal 340B program has been hijacked by large hospital and pharmacy systems, thereby raising health care costs for all Virginians by inflating the cost of the discounted drugs.

10/06/2025

: Life sciences companies have committed to investing over $1.5 billion a day in 2025 to construct and expand U.S. infrastructure and improve America’s national security. See this new U.S. Biopharma Investment Watch from : https://www.weworkforhealth.org/post/new-u-s-biopharma-investment-watch-425b-committed-in-2025

09/23/2025

"Our investment in Virginia underscores our commitment to U.S. innovation and manufacturing - creating high-quality jobs, strengthening communities and advancing the health and well-being of Americans nationwide," David A. Ricks, CEO of Eli Lilly.

The pharmaceutical giant says it chose Goochland over hundreds of applicants. The manufacturing plant will create 650 jobs.

09/22/2025

"The 340B program is a classic example of a well-intended policy that has caused unintended harm. Congress established the program in 1992 to help hospitals that disproportionately serve Medicaid and low-income patients."

Rich hospitals have been gaming a discount drug program for the poor.

09/22/2025

"Instead of embracing the socialist price controls embedded in MFN, President Trump should stay the course on his America First approach, which includes shifting to a direct-to-patient sales model, strong trade negotiations to make other countries pay their fair share, reining in insurer-PBM middlemen, and rolling back the IRA’s damaging price controls. America’s seniors and our future as the global leader in health care depend on it."

President Trump is right to call out foreign countries for freeloading off American medical innovation. However, the push by some politicians, like Senator Bernie Sanders of Vermont, to adopt a Most F

09/19/2025

Survey Shows Vast Majority of U.S. Doctors Place Higher Value on Medicines vs. German Health Authorities

Read more⬇

Washington, D.C. — A new survey of U.S. physicians shows that their judgments on the clinical value of medicines differ dramatically from those of the German health authority (G-BA), raising serious concern about the potential adoption of European-style drug pricing as proposed under a Most Favore...

09/18/2025

"The overwhelming majority of small and independent healthcare providers fear that Medicare’s upcoming negotiation of Part B drug prices could inadvertently curb patients’ access to certain lifesaving medicines, according to results from a survey conducted by Avalere Health and released in partnership with the National Infusion Center Association (NICA)."

Read more⬇

AUSTIN, Texas (September 9, 2025) — The overwhelming majority of small and independent healthcare providers fear that Medicare’s upcoming negotiation of Part B drug prices could […]